SG10202013187PA - Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders - Google Patents
Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disordersInfo
- Publication number
- SG10202013187PA SG10202013187PA SG10202013187PA SG10202013187PA SG10202013187PA SG 10202013187P A SG10202013187P A SG 10202013187PA SG 10202013187P A SG10202013187P A SG 10202013187PA SG 10202013187P A SG10202013187P A SG 10202013187PA SG 10202013187P A SG10202013187P A SG 10202013187PA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- pharmaceutical compositions
- inflammatory disorders
- novel salts
- salts
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L63/00—Network architectures or network communication protocols for network security
- H04L63/04—Network architectures or network communication protocols for network security for providing a confidential data exchange among entities communicating through data packet networks
- H04L63/0428—Network architectures or network communication protocols for network security for providing a confidential data exchange among entities communicating through data packet networks wherein the data content is protected, e.g. by encrypting or encapsulating the payload
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L63/00—Network architectures or network communication protocols for network security
- H04L63/06—Network architectures or network communication protocols for network security for supporting key management in a packet data network
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L63/00—Network architectures or network communication protocols for network security
- H04L63/08—Network architectures or network communication protocols for network security for authentication of entities
- H04L63/0861—Network architectures or network communication protocols for network security for authentication of entities using biometrical features, e.g. fingerprint, retina-scan
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L63/00—Network architectures or network communication protocols for network security
- H04L63/20—Network architectures or network communication protocols for network security for managing network security; network security policies in general
- H04L63/205—Network architectures or network communication protocols for network security for managing network security; network security policies in general involving negotiation or determination of the one or more network security mechanisms to be used, e.g. by negotiation between the client and the server or between peers or by selection according to the capabilities of the entities involved
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L67/00—Network arrangements or protocols for supporting network services or applications
- H04L67/01—Protocols
- H04L67/10—Protocols in which an application is distributed across nodes in the network
- H04L67/104—Peer-to-peer [P2P] networks
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L67/00—Network arrangements or protocols for supporting network services or applications
- H04L67/50—Network services
- H04L67/51—Discovery or management thereof, e.g. service location protocol [SLP] or web services
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/80—Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W8/00—Network data management
- H04W8/22—Processing or transfer of terminal data, e.g. status or physical capabilities
- H04W8/24—Transfer of terminal data
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W92/00—Interfaces specially adapted for wireless communication networks
- H04W92/16—Interfaces between hierarchically similar devices
- H04W92/18—Interfaces between hierarchically similar devices between terminal devices
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Signal Processing (AREA)
- Computer Networks & Wireless Communication (AREA)
- Computer Security & Cryptography (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Computing Systems (AREA)
- Computer Hardware Design (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Databases & Information Systems (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1402071.3A GB201402071D0 (en) | 2014-02-07 | 2014-02-07 | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202013187PA true SG10202013187PA (en) | 2021-02-25 |
Family
ID=50390572
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202013187PA SG10202013187PA (en) | 2014-02-07 | 2015-02-04 | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| SG11201606433PA SG11201606433PA (en) | 2014-02-07 | 2015-02-04 | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201606433PA SG11201606433PA (en) | 2014-02-07 | 2015-02-04 | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
Country Status (28)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201402070D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| KR20170134750A (ko) * | 2015-04-13 | 2017-12-06 | 갈라파고스 엔.브이. | 염증 질환의 치료 방법 |
| ES2959612T3 (es) * | 2015-04-13 | 2024-02-27 | Galapagos Nv | Métodos para el tratamiento de trastornos cardiovasculares |
| WO2016205334A1 (en) | 2015-06-16 | 2016-12-22 | Vascular Strategies Llc | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof |
| CN105198877B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物g晶型及其制备方法 |
| CN105111207B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物d晶型及其制备方法 |
| CN105198878B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物f晶型及其制备方法 |
| CN105198880B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物a晶型及其制备方法 |
| CN105218539B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物b晶型及其制备方法 |
| CN105198876B (zh) * | 2015-09-18 | 2017-09-29 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物h晶型及其制备方法 |
| CN105111206B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物e晶型及其制备方法 |
| CN105198879B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物c晶型及其制备方法 |
| WO2017106568A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer |
| US20170173034A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
| US20170174788A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders |
| CN105669669A (zh) * | 2016-03-04 | 2016-06-15 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物的a晶型、b晶型、d晶型、g晶型和m晶型及其制备方法 |
| EP3434675A4 (en) * | 2016-03-21 | 2019-03-06 | Crystal Pharmatech Co., Ltd | HYDROCHLORIDE SALT CREAM OF A MEDICAMENT FOR TREATING OR PREVENTING JAC-ASSOCIATED DISEASES AND METHOD OF PRODUCTION THEREOF |
| US10633376B2 (en) | 2016-08-03 | 2020-04-28 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline forms of JAK1-selective inhibitor, processes for preparation and use thereof |
| AU2017358703A1 (en) | 2016-11-10 | 2019-05-09 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases |
| GB201702603D0 (en) | 2017-02-17 | 2017-04-05 | Galápagos Nv | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| JOP20180018A1 (ar) * | 2017-03-14 | 2019-01-30 | Gilead Sciences Inc | تركيبات صيدلية تتضمن مثبط jak |
| GB201808575D0 (en) | 2018-05-24 | 2018-07-11 | Galapagos Nv | Methods for the treatment of psoriatic arthrits |
| US10815227B2 (en) | 2018-08-27 | 2020-10-27 | Cadila Healthcare Limited | Processes for the preparation of filgotinib |
| US11882438B2 (en) * | 2018-10-29 | 2024-01-23 | Zorday IP, LLC | Network-enabled electronic cigarette |
| WO2020177705A1 (zh) * | 2019-03-05 | 2020-09-10 | 苏州科睿思制药有限公司 | Filgotinib的马来酸盐晶型CSI及其制备方法和用途 |
| AU2020251400B2 (en) * | 2019-03-30 | 2025-02-06 | Unichem Laboratories Limited | Novel process for the preparation of filgotinib and intermediates thereof |
| WO2021044327A1 (en) * | 2019-09-03 | 2021-03-11 | Dr. Reddy's Laboratories Limited | Solid forms of filgotinib maleate and processes thereof |
| CN114075188A (zh) * | 2020-08-11 | 2022-02-22 | 南京柯菲平盛辉制药有限公司 | 芳香杂环酰胺类化合物及其制备方法和医药用途 |
| CN113773322B (zh) * | 2021-11-10 | 2022-02-11 | 奥锐特药业(天津)有限公司 | 一种Filgotinib的制备方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2549632B2 (ja) * | 1986-08-20 | 1996-10-30 | 三井石油化学工業株式会社 | オレフインの重合方法 |
| AU2318600A (en) | 1999-01-29 | 2000-08-18 | Chugai Seiyaku Kabushiki Kaisha | Chondrongenesis promotors and indolin-2-one derivatives |
| US20040138285A1 (en) | 2001-04-27 | 2004-07-15 | Makoto Okazaki | Chondrogenesis promoters |
| US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| JPWO2004039816A1 (ja) * | 2002-10-29 | 2006-03-02 | 塩野義製薬株式会社 | セフェム化合物の無機酸塩の結晶 |
| BRPI0407384A (pt) | 2003-02-14 | 2006-02-21 | Pfizer Prod Inc | piridinas-triazóis como compostos antiinflamatórios |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| JP2008503712A (ja) | 2004-06-21 | 2008-02-07 | ガラパゴス・ナムローゼ・フェンノートシャップ | 骨関節炎治療の方法及び手段 |
| US20090209577A1 (en) | 2004-08-18 | 2009-08-20 | Pfizer Inc. | Novel Triazolopyridine Compounds |
| EP1799680A2 (en) | 2004-10-07 | 2007-06-27 | Warner-Lambert Company LLC | Triazolopyridine derivatives as antibacterial agents |
| GB0515026D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| ES2549862T3 (es) | 2006-08-30 | 2015-11-02 | Cellzome Limited | Derivados de triazol como inhibidores de quinasa |
| JP5352476B2 (ja) | 2007-06-05 | 2013-11-27 | 武田薬品工業株式会社 | キナーゼ阻害剤としての二環式複素環化合物 |
| EP2178868A1 (en) | 2007-07-18 | 2010-04-28 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| EA201070328A1 (ru) | 2007-08-31 | 2010-08-30 | Мерк Сероно С.А. | Соединения триазолопиридина и их применение в качестве ингибиторов ask |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| RU2561104C2 (ru) | 2008-06-20 | 2015-08-20 | Дженентек, Инк. | Триазолопиридиновые соединения-ингибиторы jak и способы |
| WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| WO2010010186A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| US20110124692A1 (en) | 2008-07-31 | 2011-05-26 | Daiichi Sankyo Company, Limited | Crystalline forms of thiazolidinedione compound and its manufacturing method |
| AU2010254806C1 (en) | 2009-06-05 | 2016-07-07 | Cephalon, Inc. | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| CA2775027A1 (en) | 2009-09-25 | 2011-03-31 | Kyorin Pharmaceutical Co., Ltd. | Maleic acid salt and crystal thereof |
| CN102146082A (zh) | 2010-02-04 | 2011-08-10 | 江苏恒瑞医药股份有限公司 | 吡咯并n杂环类衍生物的可药用的盐、其制备方法及其在医药上的应用 |
| JP2013049632A (ja) * | 2011-08-30 | 2013-03-14 | Kowa Co | ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び／又は治療剤 |
| SA112330992B1 (ar) * | 2011-11-10 | 2015-09-13 | كيورين فارماسوتيكال كو.، ليمتد | صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي |
| WO2013173506A2 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| SG10201700125VA (en) | 2012-06-22 | 2017-02-27 | Galapagos Nv | Aminotriazolopyridine For Use In The Treatment Of Inflammation, And Pharmaceutical Compositions Thereof |
| GB201402071D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| KR20170134750A (ko) | 2015-04-13 | 2017-12-06 | 갈라파고스 엔.브이. | 염증 질환의 치료 방법 |
| ES2959612T3 (es) | 2015-04-13 | 2024-02-27 | Galapagos Nv | Métodos para el tratamiento de trastornos cardiovasculares |
| US20170173034A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
| JOP20180018A1 (ar) | 2017-03-14 | 2019-01-30 | Gilead Sciences Inc | تركيبات صيدلية تتضمن مثبط jak |
| GB201808575D0 (en) | 2018-05-24 | 2018-07-11 | Galapagos Nv | Methods for the treatment of psoriatic arthrits |
-
2014
- 2014-02-07 GB GBGB1402071.3A patent/GB201402071D0/en not_active Ceased
-
2015
- 2015-02-04 MX MX2016010068A patent/MX376000B/es active IP Right Grant
- 2015-02-04 NZ NZ722603A patent/NZ722603A/en unknown
- 2015-02-04 HR HRP20210194TT patent/HRP20210194T1/hr unknown
- 2015-02-04 RS RS20210134A patent/RS61450B1/sr unknown
- 2015-02-04 PT PT157049743T patent/PT3102575T/pt unknown
- 2015-02-04 US US14/614,396 patent/US9382247B2/en active Active
- 2015-02-04 SG SG10202013187PA patent/SG10202013187PA/en unknown
- 2015-02-04 SM SM20210060T patent/SMT202100060T1/it unknown
- 2015-02-04 SI SI201531491T patent/SI3102575T1/sl unknown
- 2015-02-04 CN CN202010324636.7A patent/CN111499630A/zh active Pending
- 2015-02-04 SG SG11201606433PA patent/SG11201606433PA/en unknown
- 2015-02-04 EP EP15704974.3A patent/EP3102575B1/en active Active
- 2015-02-04 CA CA2938219A patent/CA2938219C/en active Active
- 2015-02-04 WO PCT/EP2015/052242 patent/WO2015117981A1/en active Application Filing
- 2015-02-04 EA EA201691584A patent/EA032596B1/ru unknown
- 2015-02-04 EP EP20211405.4A patent/EP3842432A1/en not_active Withdrawn
- 2015-02-04 MX MX2020003368A patent/MX395415B/es unknown
- 2015-02-04 PL PL15704974T patent/PL3102575T3/pl unknown
- 2015-02-04 DK DK15704974.3T patent/DK3102575T3/da active
- 2015-02-04 EA EA201990330A patent/EA201990330A1/ru unknown
- 2015-02-04 AU AU2015215045A patent/AU2015215045B2/en active Active
- 2015-02-04 KR KR1020167023807A patent/KR102478614B1/ko active Active
- 2015-02-04 LT LTEP15704974.3T patent/LT3102575T/lt unknown
- 2015-02-04 CN CN201580006893.3A patent/CN105960407A/zh active Pending
- 2015-02-04 JP JP2016550633A patent/JP2017505329A/ja active Pending
- 2015-02-04 ES ES15704974T patent/ES2853375T3/es active Active
- 2015-02-04 IL IL246833A patent/IL246833B/en unknown
- 2015-02-04 HU HUE15704974A patent/HUE053309T2/hu unknown
- 2015-02-06 UY UY0001035984A patent/UY35984A/es not_active Application Discontinuation
- 2015-02-06 TW TW104104160A patent/TWI767878B/zh active
- 2015-02-06 TW TW110136599A patent/TWI792593B/zh active
- 2015-02-06 AR ARP150100351A patent/AR099307A1/es unknown
-
2016
- 2016-07-01 US US15/200,228 patent/US20160376269A1/en not_active Abandoned
-
2017
- 2017-07-10 US US15/645,308 patent/US10708263B2/en active Active
-
2019
- 2019-04-08 AU AU2019202441A patent/AU2019202441B2/en active Active
- 2019-09-30 US US16/588,207 patent/US10919890B2/en active Active
-
2020
- 2020-01-28 JP JP2020011555A patent/JP2020097595A/ja active Pending
- 2020-10-26 AU AU2020260391A patent/AU2020260391B2/en active Active
-
2021
- 2021-01-08 US US17/144,788 patent/US11667633B2/en active Active
- 2021-02-01 CY CY20211100080T patent/CY1124349T1/el unknown
-
2022
- 2022-09-23 AU AU2022235624A patent/AU2022235624B2/en active Active
-
2023
- 2023-04-25 US US18/306,867 patent/US12234235B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL246833A0 (en) | New salts and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| IL256624B (en) | Pharmaceutical compounds and preparations thereof for the treatment of inflammatory disorders | |
| IL255109A0 (en) | New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders | |
| GB201402070D0 (en) | Pharmaceutical compositions for the treatment of inflammatory disorders | |
| GB201411241D0 (en) | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| EP3183005A4 (en) | Methods and compositions for the treatment of metabolic disorders | |
| GB201401086D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| HUE037179T2 (hu) | Gyógyászati kompozíciók izom-rendellenességek kezelésére | |
| GB201610056D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis | |
| GB201610055D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis | |
| PL3164110T3 (pl) | Kompozycje farmaceutyczne do leczenia łuszczycy | |
| GB201513345D0 (en) | Methods for the treatment of Inflammatory disorders | |
| GB201507113D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201506419D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201506229D0 (en) | Methods For the Treatment Of Inflammatory Disorders |